Metastasis Cancer Treatment Market size & Market Analysis

The global Metastasis Cancer Treatment Market size in terms of revenue was worth of $63.18 Billion in 2020 and is expected to reach $161.67 Billion in 2027, growing at CAGR of 12.3% from 2021 to 2027.

Metastasis Cancer Treatment Market size & Market Analysis

Metastasis cancer represents the advanced form of cancer, which occurs when the cancer cells start spreading from the site of origin to different parts of the body. Treatment for Metastasis cancer aims to slow the expansion or spread of the cancer. Treatment depends on the sort of cancer, where it started, the dimension and location of the metastasis and other factors. The treatment for Metastasis cancer is often different from the ones used for a normal tumor. Treatment of Metastasis cancer is often not curable and is mainly focused on providing relaxing care. Several manufactures are investing in oncology market and are making vigorous efforts for the supply of cost-effective cancer treatment drugs used in chemotherapy, radiation therapy and hormone therapy. Patients all over the world are looking forward for advanced cancer therapy drugs to capture their condition, which is turn, is increasing the adoption rate of the Metastasis cancer treatment drugs.

Metastasis occurs when cancer progresses to different parts of the body from where it originated and it is the culmination of neoplastic progression. Cancer metastasis is a major challenge in cancer treatment as it is difficult to diagnose and treat. Metastasis accounts for 90% of cancer associated mortality and only a small number of patients with metastatic cancer can be treated with conventional strategies such as chemotherapy, radiotherapy and surgical removal.

Metastasis Cancer Treatment Market size & Market Analysis

Increasing focus on development of new strategies to prevent metastasis, rapid adoption of stem cells and oncolytic viruses to treat metastatic cancer, and growing caseload of cancer across the globe are some key factors expected to drive market revenue growth over the forecast period. In addition, increasing research and development activities to understand molecular mechanisms of metastasis and rising number of clinical trials to develop personalized treatments that can specifically target metastases are some other key factors expected to contribute revenue growth of the market going ahead.

The major drivers for the global Metastasis cancer treatment market growth are rising prevalence of cancer and high medical needs of patients who have Metastasis cancer. Rising prevalence of Metastasis cancer is one of the major factors expected to drive the growth of the global Metastasis cancer treatment market. It is estimated that metastasis is responsible for about 90% of cancer deaths. This estimate has changed little in more than 50 years, according to National Center for Biotechnology Information. The increasing cancer burden is due to several factors, including population growth and ageing as well as the changing prevalence of certain causes of cancer linked to social and economic development. Breast cancer is the second most common cause of death from cancer in 6% women. It is estimated that 42,690 people will die from breast cancer, according to American Society of Clinical Oncology. Metastasis breast cancer will cause the vast majority of those deaths. However, high cost of Metastasis cancer treatment may hamper the growth of this market. In spite of that, increasing number of pharmaceutical, biotechnology and diagnostic companies are focusing on research and development of innovative oncology medicines to provide advanced treatment which may create more opportunities for the further growth of the market.

Metastasis Cancer Treatment Market size & Market Analysis

Metastasis is the major reason for treatment failure in cancer patients and accounts for majority of cancer-related deaths. Metastasis also causes treatment failure even in tumors that are sensitive to chemotherapy or radiotherapy. Metastatic tumors are difficult to treat with conventional therapy due to their anatomically diffuse localization and resistance to cytotoxic agents. Rapid technological advancements in imaging and cancer cell identification have significantly improved understanding of cancer metastasis. Treatment of metastatic cancer primarily aims to slow the growth or spread of cancer and typically requires systemic therapy or oral or intravenous medications to reach cancer cells throughout the body.

Other treatment approaches include immunotherapy, radiation therapy, surgical intervention, or a combination of these treatments. In addition, clinical trials offer access top novel treatment approaches that can prove to be more appropriate and effective as compared to standard of care options. Various therapeutic options are available to ease side effects and enhance quality of life of patients even after metastatic cancer has stopped responding to treatments. Development of new strategies to manage and treat metastatic cancer and advancements in stem cell therapy are some factors expected to drive market revenue growth over the forecast period.

However, difficulties associated with the treatment of metastatic cancer, high costs of cancer treatment, and resistance of metastatic cells to conventional treatment approaches and cytotoxic agents are some key factors expected to restrain market growth to a certain extent over the forecast period. In addition, lack of knowledge regarding metastatic processes, recurrence of cancer, and systemic side effects of treatment are some other factors expected to hamper market growth to a certain extent over the forecast period.  

North America is the highest revenue generating market for Metastasis cancer treatment solutions. The rate of diagnosis is high in this region due to advances healthcare infrastructure and awareness among the people. According to American cancer society; in 2016; there were approximately 3.5 million women living with an antiquity of breast cancer in the United States. More than 16.9 million Americans with a history of cancer were alive on January 1st, 2019, and this number is projected to grow to more than 22.1 million by January 1st, 2030, according to Carevive Systems, Inc. Europe is second largest region for this market due to rising Advancements in immune-oncology and precision medicine. Immense scientific innovation in the field of oncology has resulted in higher regulatory approval rates of cancer treatment drugs used in chemotherapy, radiation therapy, and hormone therapy, among others in this region. In 2017, more than 3,500 radiation therapy machines were used by hospitals and providers of ambulatory health care in the European Union (EU). The performance of breast-protection surgery has increased, and the use of neoadjuvant therapy to downstage locally advanced breast cancer has become more common in the Asia–Pacific region.

Metastasis Cancer Treatment – Main Players :

List of main players in the Global Metastasis Cancer Treatment Market size & Market Analysis :

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Eli-Lilly and Company
  • Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.

Source Metastasis Cancer Treatment Market size & Market Analysis :